Multidrug Resistance Protein (MRP)-mediated Transport of Leukotriene CGraphic and Chemotherapeutic Agents in Membrane Vesicles

DEMONSTRATION OF GLUTATHIONE-DEPENDENT VINCRISTINE TRANSPORT (*)

  1. Douglas W. Loe(1),
  2. Kurt C. Almquist(1)(2)(§),
  3. Roger G. Deeley(1)(2)(¶) and
  4. Susan P. C. Cole(1)(2)(**)
  1. From the (1)Cancer Research Laboratories and
  2. (2)Department of Pathology, Queen's University, Kingston, Ontario, K7L 3N6 Canada
  1. ** Career Scientist of the Ontario Cancer Foundation. To whom correspondence and reprint requests should be addressed:
    Cancer Research Laboratories, Rm. 328, Botterell Hall, Queen's University, Kingston, Ontario, Canada, K7L 3N6.
    Tel.: 613-545-6507; Fax: 613-545-6830.

Abstract

The 190-kDa multidrug resistance protein (MRP) has recently been associated with the transport of cysteinyl leukotrienes and several glutathione (GSH) S-conjugates. In the present study, we have examined the transport of leukotriene CGraphic (LTCGraphic) in membrane vesicles from MRP-transfected HeLa cells (T14), as well as drug-selected H69AR lung cancer cells which express high levels of MRP. VGraphic and KGraphic values for LTCGraphic transport by membrane vesicles from T14 cells were 529 ± 176 pmol mgGraphic minGraphic and 105 ± 31 nM, respectively. At 50 nM LTCGraphic, the KGraphic (ATP) was 70 μM. Transport in T14 vesicles was osmotically-sensitive and was supported by various nucleoside triphosphates but not by non- or slowly-hydrolyzable ATP analogs. LTCGraphic transport rates in membrane vesicles derived from H69AR cells and their parental and revertant variants were consistent with their relative levels of MRP expression. A 190-kDa protein in T14 membrane vesicles was photolabeled by [3H]LTCGraphic and immunoprecipitation with MRP-specific monoclonal antibodies (mAbs) confirmed that this protein was MRP. LTCGraphic transport was inhibited by an MRP-specific mAb (QCRL-3) directed against an intracellular conformational epitope of MRP, but not by a mAb (QCRL-1) which recognizes a linear epitope. Photolabeling with [3H]LTCGraphic was also inhibitable by mAb QCRL-3 but not mAb QCRL-1. GSH did not inhibit LTCGraphic transport. However, the ability of alkylated GSH derivatives to inhibit transport increased markedly with the length of the alkyl group. S-Decylglutathione was a potent competitive inhibitor of [3H]LTCGraphic transport (KGraphicGraphic 116 nM), suggesting that the two compounds bind to the same, or closely related, site(s) on MRP. Chemotherapeutic agents including colchicine, doxorubicin, and daunorubicin were poor inhibitors of [3H]LTCGraphic transport. Taxol, VP-16, vincristine, and vinblastine were also poor inhibitors of LTCGraphic transport but inhibition by these compounds was enhanced by GSH. Uptake of [3H]vincristine into T14 membrane vesicles in the absence of GSH was low and not dependent on ATP. However, in the presence of GSH, ATP-dependent vincristine transport was observed. Levels of transport increased with concentrations of GSH up to 5 mM. The identification of an MRP-specific mAb that inhibits LTCGraphic transport and prevents photolabeling of MRP by LTCGraphic, provides conclusive evidence of the ability of MRP to transport cysteinyl leukotrienes. Our studies also demonstrate that MRP is capable of mediating ATP-dependent transport of vincristine and that transport is GSH-dependent.

Footnotes

  • § Supported by an MRCC studentship.

  • Stauffer Research Professor of Queen's University.

  • * This work was supported in part by a grant from the Medical Research Council of Canada (MRCC) (to S. P. C. C. and R. G. D.).

  • 1 The abbreviations used are:

    MRP

    multidrug resistance protein

    AMP-PCP

    β,Graphic-methyleneadenosine 5′-triphosphate

    AMP-PNP

    adenosine 5′-[β,Graphic-imido]triphosphate

    ATPGraphicS

    adenosine 5′-O-(3-thiotriphosphate)

    LTCGraphic

    leukotriene CGraphic

    LTBGraphic

    leukotriene BGraphic

    mAb

    monoclonal antibody

    VCR

    vincristine

    PAGE

    polyacrylamide gel electrophoresis.

    • Received November 30, 1995.
    • Revision received January 17, 1996.
« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement